148 results
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
12 Mar 24
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
4:10pm
and meaningful solutions in the acute care and oncology care settings.”
Business Highlights
The ZYNRELEF Vial Access Needle (“VAN”) program, to allow
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
24 Jan 24
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
8:01am
Access Needle (“VAN”) later this year, are expected to have a significant positive impact for ZYNRELEF and the Company,” said Craig Collard, Chief
8-K
EX-99.1
9c3s1qxeym29rsv 050g
11 Jan 24
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-99.1
yqje7z29tggb 014e
14 Nov 23
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
4:10pm
424B3
jmzx1 7hapz37t
5 Sep 23
Prospectus supplement
9:14pm
8-K
EX-10.1
e4hz63l
24 Jul 23
Heron Therapeutics Announces $30 Million Private Placement Financing
9:12am
8-K
EX-99.1
5p8el0amwyloba
29 Dec 22
Other Events
9:10am
424B5
zzz17bq
20 Oct 22
Prospectus supplement for primary offering
4:06pm